Effect of gonadotropin-releasing hormone analog treatment on final height in girls aged 6–10 years with central precocious and early puberty Gonadotropin releasing hormon analog tedavisinin santral erken ergenlikli 6–10 yaş arası kızlarda final boya etkisi
Turkish Archives of Pediatrics, cilt.55, sa.4, ss.361-369, 2020 (ESCI, Scopus, TRDizin)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 55 Sayı: 4
- Basım Tarihi: 2020
- Doi Numarası: 10.14744/turkpediatriars.2020.01700
- Dergi Adı: Turkish Archives of Pediatrics
- Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, TR DİZİN (ULAKBİM)
- Sayfa Sayıları: ss.361-369
- Anahtar Kelimeler: Central precocious puberty, early puberty, final height, gonadotropin-releasing hormone analog treatment, rapidly progressive puberty
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Aim: To determine the effects of gonadotropin-releasing hormone analog treatment on final height and body mass index in girls with central precocious puberty. Material and Methods: All cases with diagnosis age <8 years constituted group 1 (n=19) and those with ≥8 years constituted group 2 (n=35). Results: There was no significant difference in height standard deviation score, body mass index standard deviation score, bone age/chrono-logic age, predicted final height at the time of diagnosis, and follow-up between group 1 and group 2. There was no significant difference in final height (standard deviation score) between the groups. The number of obese and overweight cases at diagnosis and final height was simi-lar. The target height (standard deviation score), predicted final height (standard deviation score), and final height (standard deviation score) were similar in both Group 1 and Group 2. Conclusion: We found that between the ages of 6–9.8 years, girls with central precocious puberty who received gonadotropin-releasing hor-mone analog treatment reached a final height within their target height range. It is concluded that gonadotropin-releasing hormone analog treatment increases body mass index during treatment and when patients reach the final height, they return to their pretreatment body mass index. Younger age and greater height at the time of diagnosis are the positive factors on final height.